New drug - Ecalta

Pfizer has launched Ecalta (anidulafungin) for the treatment of invasive candidiasis in adult non-neutropenic patients.

PHARMACOLOGY
Anidulafungin is an antimycotic agent with fungicidal activity against Candida species and activity against regions of active cell growth of the hyphae of Aspergillus fumigatus. It exerts its effect through selective inhibition of 1,3-beta-D glucan synthase, an enzyme present in fungal but not mammalian cells, thereby inhibiting the formation of 1,3-beta-D glucan, an essential component of the fungal cell wall.

 

CLINICAL STUDIES
Anidulafungin was evaluated in a double-blind, non-inferiority study1 comparing it with fluconazole for the treatment of candidaemia and other forms of invasive candidiasis in patients aged 16 years and over (n=245).


Patients were randomised to intravenous anidulafungin (200mg on day one then 100mg daily, n=127) or intravenous fluconazole (800mg on day one then 400mg daily, n=118).


The primary endpoint was global success at the end of intravenous therapy, defined as both clinical success (resolution of signs and symptoms of invasive candidiasis and no need for additional systemic antifungal therapy) and microbiological success (eradication of Candida species present at baseline, as determined on follow-up culture, or the presumed eradication if culture data not available for a patient with a successful clinical response).


Overall, a successful response was achieved in 75.6 per cent of patients in the anidulafungin group compared with 60.2 per cent of those in the fluconazole group.


In patients with candidaemia only, 75.9 per cent in the anidulafungin group and 61.2 per cent in the fluconazole group achieved a successful response. Similarly, among patients with other forms of invasive candidiasis a greater proportion of patients in the anidulafungin group achieved a successful response than in the fluconazole group.

1. Reboli A, Rotstein C, Pappas P et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007: 356: 2472–82.

 

Further information: Pfizer 01304 616161


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases